Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients.

@article{Salvadori2001TherapeuticEO,
  title={Therapeutic equivalence of mycophenolate sodium versus mycophenolate mofetil in de novo renal transplant recipients.},
  author={M Salvadori},
  journal={Transplantation proceedings},
  year={2001},
  volume={33 7-8},
  pages={
          3245-7
        }
}
MYCOPHENOLIC acid (MPA) is a potent, selective, non-competitive, reversible inhibitor of inosine mono phosphate dehydrogenase. However, use of immunosuppressive agents containing MPA as the active compound, such as mycophenolate mofetil (MMF), may be limited by various side effects. These include hematological adverse events such as anemia, thrombocytopenia, and leucopenia, increased risk of cytomegalovirus (CMV) and opportunistic infections and gastrointestinal (GI) disorders, such as nausea… CONTINUE READING
BETA